• Mashup Score: 2
    Program Guide – ASCO Meeting Program Guide - 1 year(s) ago

    AuthorsDeborah SchragMemorial Sloan Kettering Cancer CenterDeborah Schrag, Qian Shi, Martin Weiser, Marc Gollub, Leonard Saltz, Benjamin Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn Goodman, Robert McWilliams, Jeffrey Farma, Thomas George, Hagen Kennecke, Alan Venook, Eileen O’Reilly, Jeffrey Meyerhardt, Amylou Dueck, Ethan Basch, George Chang, Harvey MamonOrganizationsMemorial Sloan Kettering…

    Source: meetings.asco.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      🎉Another GI onc plenary at #ASCO23 this year! 🎉PROSPECT: A randomized phase III trial of neoadjuvant chemoRT vs neoadjuvant FOLFOX with selective use of chemoRT, followed by TME for treatment of locally advanced rectal cancer (Alliance N1048).https://t.co/qdv6YcfBan

  • Mashup Score: 0
    Here's a new data point for cancer patients to consider: 'time toxicity' - 1 year(s) ago

    “As an oncologist, patients rely on us to convey to them the relative risks and benefits of a treatment. And I think we should consider time toxicity more explicitly in these conversations.”

    Source: STAT
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      Here’s a new data point for cancer patients to consider: ‘time toxicity’ https://t.co/lBxb5ybtV3 via @statnews - while I agree time toxicity is important please also read the counterpoint by Tony Back @guptaarjun90

  • Mashup Score: 0
    I Want to Kill you: Facing a Threat and Finding Support and Safety - 1 year(s) ago

    Listen to this episode from Cancer Stories: The Art of Oncology on Spotify. Listen to ASCO’s Journal of Clinical Oncology essay, “I Want to Kill You” by Dr. Noelle LoConte, Associate Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. The essay is followed by an interview with LoConte and host Dr. Lidia Schapira. LoConte shares her experience of a patient’s…

    Source: Spotify
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      @JCO_ASCO Here is a companion podcast about this where I speak to the editor about this https://t.co/uNJHSDV5dI

  • Mashup Score: 0
    Providing power to Ukraine in the dark and cold of winter - 1 year(s) ago

    ‘My partners at that time told me that what I’m doing is insane, but it’s going to save thousands of lives,’ said Anya Verkhovskaya, a Milwaukee resident who is working …

    Source: PBS Wisconsin
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      Ongoing amazing work from @DrDavoha and @NataliyaUboha in their relentless support of Ukraine. So very proud of both of you! Providing power to Ukraine in the dark and cold of winter https://t.co/Y7Gcub5Hps

  • Mashup Score: 0
    Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life - PubMed - 1 year(s) ago

    While costs related to end-of-life care for nearly all cost categories have remained relatively stable, oncology drug costs overall and immunotherapy costs specifically have accelerated and account almost entirely for the observed overall increase in outpatient cost burden for Medicare.

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      Important study in the red journal (@IJROBP) by Mantz, et al, showing a 12% increase in spending at end of life (last 6 mo) among Medicare beneficiaries with #cancer (both solid tumor and heme) - driven almost entirely by immunotherapy costs https://t.co/kj1hZ2QdRs

  • Mashup Score: 21
    Genitourinary Syndrome of Menopause and the False Promise of Vaginal Laser Therapy - 1 year(s) ago

    Symptoms of genitourinary syndrome of menopause (GSM) affect up to 84% of individuals in menopause.1 If untreated, many individuals may have symptoms for decades, since GSM does not improve over time. While some individuals may manage with vaginal moisturizers and lubricants, many need therapy in…

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      Really well done editorial by @DrJenGunter about another negative trial of vaginal laser therapy, this time in survivors of breast ca (tl;dr don’t do it) Genitourinary Syndrome of Menopause & the False Promise of Vaginal Laser Therapy https://t.co/oNGjaEoR1q via @JAMANetworkOpen

  • Mashup Score: 0
    High School Education - 1 year(s) ago

    Our Goal The goal of ARISE is to amplify the education of student from diverse backgrounds underrepresented in biomedical fields to become competent and knowledgeable about cancer and focus on cancer careers. Engaged in year-round science education and community experiences, local high school students will participate in a diverse array of cancer focused activities to…

    Source: UWCCC Research
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of loconte
      loconte

      .@UWCarbone 's summer paid high school internship program called ARISE is now accepting applications! Learn if a career in science or oncology might be right for you! https://t.co/oYZ0iP7ut9

Load More